G.D. Kotzalidis, V. Orlandi, R. Brugnoli, P. Pancheri - Vol. 7, Dicembre 2001, num.4
Testo Immagini Bibliografia Summary Riassunto Indice
Suggerimenti per la neurobiologia
del disturbo di panico: il contributo degli studi clinici
Suggestions for the neurobiology of panic disorder: the contribution of
clinical studies
1 Pancheri L, Brugnoli R. Effetto placebo e fattori terapeutici comuni. In: Pancheri P, Cassano GB, eds. Trattato Italiano di Psichiatria, 2a Edizione. Milano: Masson 1999:3167-200.
2 Pancheri P, Pancheri L, Marconi PL, Kotzalidis GD, Brugnoli R. Psicofarmacologia dell'effetto placebo. Il trattamento dei disturbi d'ansia. Rivista di Psichiatria 1989;24:44.
3 Shear MK, Leon AC, Pollack MH, Rosenbaum JF, Keller MB. Pattern of placebo response in panic disorder. Psychopharmacol Bull 1995;31:273-8.
4 Dager SR, Khan A, Cowley D, Avery DH, Elder J, Roy-Byrne P, et al. Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull 1990;26:273-8.
5 Ninan PT. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine. J Clin Psychiatry 1997;58(Suppl 5):24-31.
6 Coryell W, Noyes R. Placebo response in panic disorder. Am J Psychiatry 1988;145:1138-40.
7 Coryell W, Noyes R Jr, Reich J. The prognostic significance of HPA-axis disturbance in panic disorder: a three-year follow-up. Biol Psychiatry 1991;29:96-102.
8 Coryell W, Noyes R Jr, Schlechte J. The significance of HPA axis disturbance in panic disorder. Biol Psychiatry 1989;25:989-1002.
9 Coryell W, Noyes R. HPA axis disturbance and treatment outcome in panic disorder. Biol Psychiatry 1988;24:762-6.
10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-III). Washington, DC: American Psychiatric Association Press 1980.
11 Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22-7.
12 Noyes R Jr, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984;41:287-92.
13 Adham N, Tamm JA, Salon JA, Vaysse PJ, Weinshank RL, Branchek TA. A single point mutation increases the affinity of serotonin 5-HT1Dalpha, 5-HT1Dbeta, 5-HT1E and 5-HT1F receptors for beta-adrenergic antagonists. Neuropharmacology 1994;33:387-91.
14 Hoyer D, Engel G, Kalkman HO. Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol. Eur J Pharmacol 1985;118:1-12.
15 Waeber C, Schoeffter P, Palacios JM, Hoyer D. 5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies. Naunyn-Schmiedebergs Arch Pharmacol 1989;340:479-85.
16 Kristiansen K, Edvardsen O, Dahl SG. Molecular modeling of the endogenous peptide Leu-Ser-Ala-Leu, pindolol, 5-hydroxytryptamine and their interactions with the human 5-hydroxytryptamine1B (5-HT1B) receptor. Receptors Channels 1998;6:31-50.
17 Newman-Tancredi A, Chaput C, Gavaudan S, Verriele L, Millan MJ. Agonist and antagonist actions of (-)pindolol at recombinant, human serotonin1A (5-HT1A) receptors. Neuropsychopharmacology 1998;18:395-8.
18 Corradetti R, Laaris N, Hanoun N, Laporte AM, Le Poul E, Hamon M, et al. Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br J Pharmacol 1998;123:449-62.
19 Assie MB, Koek W. (-)-pindolol and (+/-)-tertatolol affect rat hippocampal 5-HT levels through mechanisms involving not only 5-HT1A, but also 5-HT1B receptors. Neuropharmacology 1996;35:213-22.
20 Lejeune F, Millan MJ. Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors. Eur J Neurosci 2000;12:3265-75.
21 Sprouse J, Braselton J, Reynolds L. 5-HT1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635. Ann NY Acad Sci 1998;861:274-5.
22 Arborelius L, Linner L, Wallsten C, Ahlenius S, Svensson TH. Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo. Psychopharmacology (Berl) 2000;151:77-84.
23 Bourin M, Redrobe JP, Baker GB. Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology (Berl) 1998;136:226-34.
24 Newman-Tancredi A, Chaput C, Touzard M, Millan MJ. Pindolol antagonises G-protein activation at both pre- and postsynaptic serotonin 5-HT1A receptors: a [35S]GTPS autoradiography study. Naunyn-Schmiedebergs Arch Pharmacol 2001;363:391-8.
25 Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-9.
26 Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 2001;21:36-45.
27 Nakada S. Effects of (+/-)-pindolol over increased extracellular 5-HT level induced by fluvoxamine: regional difference in effect among the raphe, dorsal hippocampus and prefrontal cortex as measured by in vivo microdialysis technique [Japanese-English abstract]. Nihon Shinkei Seishin Yakurigaku Zasshi 2000;20:51-60.
28 Artigas F. Pindolol, 5-hydroxytryptamine, and antidepressant augmentation. Arch Gen Psychiatry 1995;52:969-71.
29 Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
30 McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990;46:163-97.
31 Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy 1987;7:87-91.
32 Ylitalo P, Linden IB, Penttila A, Vapaatalo H. Distribution of beta-adrenoceptor blocking drugs into cerebrospinal fluid in rats. Acta Pharmacol Toxicol (Copenh) 1986;58:84-7.
33 Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, et al. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 1989;46:170-7.
34 Taschner KL. A controlled comparison of clonidine and doxepin in the treatment of the opiate withdrawal syndrome. Pharmacopsychiatry 1986;19:91-5.
35 Gold MS, Redmond DE Jr, Kleber HD. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry 1979;136:100-2.
36 Gold MS, Redmond DE Jr, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978;2:599-602.
37 Esteban S, Llado J, Sastre-Coll A, Garcia-Sevilla JA. Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo. Naunyn-Schmiedebergs Arch Pharmacol 1999;360:135-43.
38 Haddjeri N, Blier P, de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 1998;51:255-66.
39 Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the alpha 2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedebergs Arch Pharmacol 1997;355:20-9.
40 Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10(Suppl 4):11-7.
41 Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999;11:81-6.
42 Ruiz-Ortega JA, Ugedo L. The stimulatory effect of clonidine on locus coeruleus neurons of rats with inactivated alpha 2-adrenoceptors: involvement of imidazoline receptors located in the nucleus paragigantocellularis. Naunyn-Schmiedebergs Arch Pharmacol 1997;355:288-94.
43 Ernsberger P, Li P, Smyth DD. 2,6-Dimethyl clonidine: alpha 2-adrenoceptor or I1-imidazoline receptor agonist? Ann N Y Acad Sci 1995;763:96-9.
44 Ruiz-Ortega JA, Ugedo L, Pineda J, Garcia-Sevilla JA. The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin. Naunyn Schmiedebergs Arch Pharmacol 1995;352:121-6.
45 Mavissakalian MR, Perel JM. Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. Arch Gen Psychiatry 1989;46:127-31.
46 Mavissakalian MR, Perel JM. The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. Psychopharmacol Bull 1996;32:143-7.
47 Auerbach SB, Lundberg JF, Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology 1995;34:89-96.
48 Béïque J-C, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998;349:129-32.
49 McLeod DR, Hoehn-Saric R, Porges SW, Kowalski PA, Clark CM. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J Clin Psychopharmacol 2000;20:615-21.
50 Mendel JG, Klein DF. Anxiety attacks with subsequent agoraphobia. Compr Psychiatry 1969;10:190-5.
51 Garakani H, Zitrin CM, Klein DF. Treatment of panic disorder with imipramine alone. Am J Psychiatry 1984;141:446-8.
52 Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580-6.
53 Giannangeli M, Cazzolla N, Luparini MR, Magnani M, Mabilia M, Picconi G, et al. Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and 1 receptor binding affinity. J Med Chem 1999;42:336-45.
54 Smith TM, Suckow RF. Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology 1985;24:1067-71.
55 Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987;144:785-7.
56 Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988;14:123-7.
57 Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-61.
58 Den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
59 Westenberg HG, den Boer JA. Serotonin-influencing drugs in the treatment of panic disorder. Psychopathology 1989;22(Suppl 1):68-77.
60 Kalus O, Asnis GM, Rubinson E, Kahn R, Friedman JM, Iqbal N, et al. Desipramine treatment in panic disorder. J Affect Disord 1991;21:239-44.
61 Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, et al. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993;29:183-8.
62 Sasson Y, Iancu I, Fux M, Taub M, Dannon PN, Zohar J. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999;9:191-6.
63 Kahn RS, Asnis GM, Wetzler S, van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl) 1988;96:360-4.
64 Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 1988;25:101-4.
65 Griez E, Pols H, Lousberg H. Serotonin antagonism in panic disorder: an open trial with ritanserin. Acta Psychiatr Belg 1988;88:372-7.
66 Den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94.
67 Kahn RS, van Praag HM. Panic disorder: a presynaptic serotonin defect? Psychiatry Res 1990;31:209-10.
68 Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res 1992;43:65-76.
69 Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994;55:479-83.
70 Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm 1982;1:406-17.
71 Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22.
72 Giannangeli M, Cazzolla N, Luparini MR, Magnani M, Mabilia M, Picconi G, et al. Effect of modifications of the alkylpiperazine moiety of trazodone on 5HT2A and alpha1 receptor binding affinity. J Med Chem 1999;42:336-45.
73 Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-36.
74 Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56(Suppl 6):3-11.
75 Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1993;16(Suppl 3):S45-S50.
76 Shukla UA, Marathe PH, Labudde JA, Pittman KA, Barbhaiya RH. Pharmacokinetics of nefazodone in the dog following single oral administration. Eur J Drug Metab Pharmacokinet 1992;17:301-8.
77 Caccia S, Ballabio M, Fanelli R, Guiso G, Zanini MG. Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography. J Chromatogr 1981;210:311-8.
78 Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988;94:137-47.
79 Callahan PM, Cunningham KA. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur J Pharmacol 1994;257:27-38.
80 Valeri P, Palmery M, Silvestrini B. Binding profile of trazodone and dapiprazole to some brain receptors. Drugs Exp Clin Res 1988;14:53-8.
81 Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile alpha1- and alpha2-adrenoceptors. BJU Int 2000;85:959-61.
82 Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994;114:559-65.
83 Gandolfi O, Roncada P, Dall'Olio R. Effects of repeated trazodone administrations on serotonergic neurotransmission: biochemical studies. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:941-52.
84 Clements-Jewery S. The development of cortical beta-adrenoceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Neuropharmacology 1978;17:779-81.
85 Alhaider AA, Mustafa AA. Enhancement of imipramine-induced rat brain beta-adrenoreceptor desensitization by subacute co-administration of trazodone, zimelidine, quipazine or 5-hydroxytryptophan. Psychopharmacology (Berl) 1991;103:351-6.
86 DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996;57:245-8.
87 Papp LA, Coplan JD, Martinez JM, de Jesus M, Gorman JM. Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharmacol 2000;20:544-6.
88 Germine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 1994;54:115-33.
89 Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;Suppl 391:31-7.
90 Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-7.
91 Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-10.
92 Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, Gorman JM. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull 1998;34:207-9.
93 Pollack MH, Worthington JJ 3rd, Otto MW, Maki KM, Smoller JW, Manfro GG, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-70.
94 Martin WR, McNicholas LF. Benzodiazepine dependence studies in rodents. NIDA Res Monogr 1980;33:37-42.
95 Kemper N, Poser W, Poser S. Benzodiazepin-Abhangigkeit. Suchtpotential der Benzodiazepine grösser als bisher angenommen. Dtsch Med Wochenschr 1980;105:1707-12.
96 Bismuth C, Le Bellec M, Dally S, Lagier G. Dépendance physique aux benzodiazépines. 6 observations. Nouv Presse Méd 1980;9:1941-5.
97 Petursson H, Lader MH. Benzodiazepine dependence. Br J Addict 1981;76:133-45.
98 Khan A, Hornblow AR, Walshe JW. Benzodiazepine dependence: a general practice survey. N Z Med J 1981;93:19-21.
99 Peroutka SJ. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 1985;20:971-9.
100 Goldberg HL. Buspirone - a new antianxiety agent not chemically related to any presently marketed drugs [proceedings]. Psychopharmacol Bull 1979;15:90-2.
101 Paul SM, Skolnick P. Comparative neuropharmacology of antianxiety drugs. Pharmacol Biochem Behav 1982;17(Suppl 1):37-41.
102 Hartmann RJ, Geller I. Effects of buspirone on conflict behavior of laboratory rats and monkeys. Proc West Pharmacol Soc 1981;24:179-81.
103 Eison AS, Eison MS, Stanley M, Riblet LA. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986;24:701-7.
104 Traber J, Davies MA, Dompert WU, Glaser T, Schuurman T, Seidel PR. Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821. Brain Res Bull 1984;12:741-4.
105 Dompert WU, Glaser T, Traber J. 3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic. Naunyn-Schmiedebergs Arch Pharmacol 1985;328:467-70.
106 Gozlan H, Ponchant M, Daval G, Verge D, Menard F, Vanhove A, et al. 125I-Bolton-Hunter-8-methoxy-2-[N-propyl-N-propylamino]tetralin as a new selective radioligand of 5-HT1A sites in the rat brain. In vitro binding and autoradiographic studies. J Pharmacol Exp Ther 1988;244:751-9.
107 Millan MJ, Colpaert FC. Attenuation of opioid induced antinociception by 5-HT1A partial agonists in the rat. Neuropharmacology 1990;29:315-8.
108 Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136:1184-7.
109 Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982;43(12 Pt 2):103-8.
110 Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987;48(Suppl):3-6.
111 Ortiz A, Pohl R, Gershon S. Azaspirodecanediones in generalized anxiety disorder: buspirone. J Affect Disord 1987;13:131-43.
112 Sheehan DV, Raj AB, Sheehan KH, Soto S. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 1988;29:815-7.
113 Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10:3-11.
114 Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11.
115 Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989;22(Suppl 1):60-7.
116 Gastfriend DR, Rosenbaum JF. Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 1989;146:914-6.
117 Pecknold JC, Luthe L, Scott-Fleury MH, Jenkins S. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 1993;13:145-9.
118 Broocks A, Bandelow B, George A, Jestrabeck C, Opitz M, Bartmann U, et al. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 2000;15:153-61.
119 Lesch K-P, Wiesmann M, Hoh A, Müller T, Disselkamp-Tietze J, Osterheider M, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl) 1992;106:111-7.
120 van Vliet IM, Westenberg HG, den Boer JA. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) 1996;127:174-80.
121 Jenck F, Martin JR, Moreau JL. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J Psychopharmacol 1999;13:166-70.
122 Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 1993;58:123-31.
123 Clarke RW, Ogilvie J, Houghton AK. Enhancement and depression of spinal reflexes by 8-hydroxy-2-(di-n-propylamino)tetralin in the decerebrated and spinalized rabbit: involvement of 5-HT1A- and non-5-HT1A-receptors. Br J Pharmacol 1997;122:631-8.
124 Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM. Cloning, expression and pharmacology of a truncated splice variant of the human5-HT7 receptor (h5-HT7b). Br J Pharmacol 1997;122:126-32.
125 Mongeau R, Marsden CA. Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. Psychopharmacology (Berl) 1997;131:321-8.
126 Griebel G, Blanchard DC, Jung A, Masuda CK, Blanchard RJ. 5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone. Pharmacol Biochem Behav 1995;51:235-44.
127 Graeff FG, Viana MB, Mora PO. Opposed regulation by dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze. Pharmacol Biochem Behav 1996;53:171-7.
128 Mizuta T, Segawa T. Chronic effects of imipramine and lithium on postsynaptic 5-HT1A and 5-HT1B sites and on presynaptic 5-HT3 sites in rat brain. Jpn J Pharmacol 1988;47:107-13.
129 Teixeira RC, Zangrossi H, Graeff FG. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol Biochem Behav 2000;65:571-6.
130 Andreatini R, Blanchard C, Blanchard R, Brandão ML, Carobrez AP, Griebel G, et al. The brain decade in debate: II. Panic or anxiety? From animal models to a neurobiological basis. Braz J Med Biol Res 2001;34:145-54.
131 McMillen BA, Scott SM, Williams HL, Sanghera MK. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn-Schmiedebergs Arch Pharmacol 1987;335:454-64.
132 Yocca FD, Eison AS, Hyslop DK, Ryan E, Taylor DP, Gianutsos G. Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment. Life Sci 1991;49:1777-85.
133 Seifritz E, Moore P, Trachsel L, Bhatti T, Stahl SM, Gillin JC. The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 1996;209:41-4.
134 Chen H, Zhang L, Rubinow DR, Chuang DM. Chronic buspirone treatment differentially regulates 5-HT1A and 5-HT2A receptor mRNA and binding sites in various regions of the rat hippocampus. Mol Brain Res 1995;32:348-53.
135 Witkin JM, Mansbach RS, Barrett JE, Bolger GT, Skolnick P, Weissman B. Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons. J Pharmacol Exp Ther 1987;243:970-7.
136 Kolasa K, Fusi R, Garattini S, Consolo S, Ladinsky H. Neurochemical effects of buspirone, a novel psychotropic drug, on the centralcholinergic system. J Pharm Pharmacol 1982;34:314-7.
137 Ryan CN, Evenden JL, Petterson M. Effects of buspirone and ipsapirone on schedule induced polydipsia: comparison with 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and raclopride. Psychopharmacology (Berl) 1993;112:34-44.
138 Maj J, Chojnacka-Wojcik E, Tatarczynska E, Klodzinska A. Central action of ipsapirone, a new anxiolytic drug, on serotoninergic, noradrenergic and dopaminergic functions. J Neural Transm 1987;70:1-17.
139 Sangdee C, Franz DN. Enhancement of central norepinephrine and 5-hydroxytryptamine transmission by tricyclic antidepressants. A comparison. Psychopharmacology (Berl) 1979;62:9-16.
140 Gloger S, Grunhaus L, Gladic D, O'Ryan F, Cohen L, Codner S. Panic attacks and agoraphobia: low dose clomipramine treatment. J Clin Psychopharmacol 1989;9:28-32.
141 Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 1998;155:603-9.
142 Lotufo-Neto F, Bernik M, Ramos RT, Andrade L, Gorenstein C, Cordas T, et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001;15:13-7.
143 Caillard V, Rouillon F, Viel JF, Markabi S, French University Antidepressant Group. Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. Acta Psychiatr Scand 1999;99:51-8.
144 Gloger S, Grunhaus L, Birmacher B, Troudart T. Treatment of spontaneous panic attacks with chlomipramine. Am J Psychiatry 1981;138:1215-7.
145 Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S. The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1992;25:63-75.
146 Papp LA, Schneier FR, Fyer AJ, Leibowitz MR, Gorman JM, Coplan JD, et al. Clomipramine treatment of panic disorder: pros and cons. J Clin Psychiatry 1997;58:423-5.
147 Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987;7:329-32 (errata corrige: J Clin Psychopharmacol 1988;8:13).
148 Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol 1990;10:119-21.
149 Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-438.
150 Pecknold JC, Luthe L, Iny L, Ramdoyal D. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramineand paroxetine binding study. J Psychiatry Neurosci 1995;20:193-8.
151 Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, et al. on behalf of The Fluoxetine Panic Disorder Study Group. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998;155:1570-17 (erratum in: Am J Psychiatry 1999;156:161).
152 Michelson D, Pollack M, Lydiard RB, Tamura R, Tepner R, Tollefson G on behalf of The Fluoxetine Panic Disorder Study Group. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. Br J Psychiatry 1999;174:213-8.
153 Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry 1999;60:299-301.
154 Saran A, Halaris A. Panic attack precipitated by fluoxetine. J Neuropsychiatry Clin Neurosci 1989;1:219-20.
155 Altshuler LL. Fluoxetine-associated panic attacks. J Clin Psychopharmacol 1994;14:433-4.
156 Young SJ. Panic associated with combining fluoxetine and bupropion. J Clin Psychiatry 1996;57:177-8.
157 Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, et al. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 1998;8:161-8.
158 Erzegovesi S, Martucci L, Henin M, Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 2001;24:31-6.
159 Price LH, Malison RT, McDougle CJ, McCance-Katz EF, Owen KR, Heninger GR. Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP). Neuropsychopharmacology 1997;17:342-50.
160 Coplan JD, Papp LA, Martinez J, Pine D, Rosenblum LA, Cooper T, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 1995;152:619-22.
161 Coplan JD, Papp LA, Pine D, Martinez J, Cooper T, Rosenblum LA, et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 1997;54:643-8.
162 Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985;27:600-11.
163 Javed A, Van de Kar LD, Gray TS. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res 1998;791:67-74.
164 Kristiansen K, Dahl SG. Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions. Eur J Pharmacol 1996;306:195-210.
165 Zgombick JM, Schechter LE, Kucharewicz SA, Weinshank RL, Branchek TA. Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes. Eur J Pharmacol 1995;291:9-15.
166 Schotte A, de Bruyckere K, Janssen PF, Leysen JE. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Res 1989;500:295-301.
167 Pols H, Zandergen J, de Loof C, Fernandez I, Griez E. Clinical effects of fluvoxamine on panic symptomatology. Acta Psychiatr Belg 1993;93:169-77.
168 Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-6.
169 Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998;31:117-21.
170 Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996;2:192-8.
171 Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32:135-41.
172 Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 1993;48:119-33.
173 van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl) 1997;129:357-64.
174 Pols HJ, Hauzer RC, Meijer JA, Verburg K, Griez EJ. Fluvoxamine attenuates panic induced by 35% CO2 challenge. J Clin Psychiatry 1996;57:539-42.
175 Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-9.
176 Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42.
177 Lecrubier Y, Bakker A, Dunbar G, Judge R, Collaborative Paroxetine Panic Study Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-52.
178 Lecrubier Y, Judge R, Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-60.
179 Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 1997;17:97-101.
180 Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 1998;155:1189-95.
181 Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-6.
182 Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, et al. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998;173:54-60.
183 Sheikh JI, Londborg P, Clary CM, Fayyad R. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 2000;15:335-42.
184 Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C. Is placebo response the same as drug response in panic disorder? Am J Psychiatry 2000;157:1014-6.
185 Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry 2000;61:922-7.
186 Feighner JP, Boyer WF. Serotonin-1A anxiolytics: an overview. Psychopathology 1989;22(Suppl 1):21-6.
187 Rapaport MH, Pollack MH, Clary CM, Mardekian J, Wolkow R. Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J Clin Psychopharmacol 2001;21:104-7.
188 Catalano G, Hakala SM, Catalano MC. Sertraline-induced panic attacks. Clin Neuropharmacol 2000;23:164-8.
189 Zinner SH. Panic attacks precipitated by sertraline. Am J Psychiatry 1994;151:147-8.
190 Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(Suppl 5):21-39.
191 Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
192 Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000;25:25-32.
193 Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-34.
194 Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 1997;22:332-40.
195 Neuger J, Wistedt B, Sinner B, Aberg-Wistedt A, Stain-Malmgren R. The effect of citalopram treatment on platelet serotonin function in panic disorders. Int Clin Psychopharmacol 2000;15:83-91.
196 Wolf WA, Kuhn DM. Modulation of serotonin release. Interactions between the serotonin transporter and autoreceptors. Ann NY Acad Sci 1990;604:505-13.
197 La Cour CM, Boni C, Hanoun N, Lesch KP, Hamon M, Lanfumey L. Functional consequences of 5-HT transporter gene disruption on 5-HT1a receptor-mediated regulation of dorsal raphe and hippocampal cell activity. J Neurosci 2001;21:2178-85.
198 Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, Lesch KP, et al. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors inknock-out mice lacking the 5-HT transporter. Eur J Neurosci 2000; 12: 2299-2310.
199 Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 1996;15:515-22.
200 Le Poul E, Boni C, Hanoun N, Laporte AM, Laaris N, Chauveau J, et al. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 2000;39:110-22.
201 Lurie M. The enigma of isoniazid. In Healy D (interviewer) The Psychopharmacologists II. London: Chapman & Hall 1998:119-34.
202 Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:397-402.
203 Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995;12:49-51.
204 Rom WN, Benner EJ. Toxicity by interaction of tricyclic antidepressant and monoamine oxidase inhibitor. Calif Med 1972;117:65-6.
205 Muscholl E. Acute hypertension after monoamine-oxidase inhibitors and the ingestion of cheese. Ger Med Mon 1965;10:337-8.
206 Tucker ES 3rd, Sirisinha I. Toxicity of monoamine oxidase inhibitors. Report of a fatal case with histochemical findings and a review of the literature. Ala J Med Sci 1965;2:301-4.
207 Pfefferbaum B, Pack R, van Eys J. Monoamine oxidase inhibitor toxicity. J Am Acad Child Adolesc Psychiatry 1989;28:954-5.
208 DeMaster EG, Sumner HW, Kaplan E, Shirota FN, Nagasawa HT. Pargyline-induced hepatotoxicity: possible mediation by the reactive metabolite, propiolaldehyde. Toxicol Appl Pharmacol 1982;65:390-401.
209 Bonkovsky HL, Blanchette PL, Schned AR. Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material. Am J Med 1986;80:689-92.
210 Runge-Morris M, Feng Y, Zangar RC, Novak RF. Effects of hydrazine, phenelzine, and hydralazine treatment on rat hepatic andrenal drug-metabolizing enzyme expression. Drug Metab Dispos 1996;24:734-7.
211 Safferman AZ, Masiar SJ. Central nervous system toxicity after abrupt monoamine oxidase inhibitor switch: a case report. Ann Pharmacother 1992;26:337-8.
212 Mendis N, Pare CM, Sandler M, Glover V, Stern GM. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology (Berl) 1981;73:87-90.
213 Liebowitz MR, Karoum F, Quitkin FM, Davies SO, Schwartz D, Levitt M, et al. Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiatry 1985;20:558-65.
214 Gasic S, Korn A, Eichler HG, Oberhummer I, Zapotoczky HG. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 1983;25:173-7.
215 Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O. Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 1987;20:262-9.
216 Rovei V, Caille D, Curet O, Ego D, Jarreau FX. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. J Neural Transm 1994;Suppl 41:339-47.
217 Martorana PA, Nitz RE. The new antidepressant pirlindole. A comparison with imipramine and tranylcypromine. Arzneimittelforschung 1979;29:946-9.
218 Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, et al. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord 1998;51:287-303.
219 Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P, et al. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995;35:633-43.
220 Warot D, Berlin I, Patat A, Durrieu G, Zieleniuk I, Puech AJ. Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects. J Clin Pharmacol 1996;36:942-50.
221 Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin G, et al. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry 1989;155(Suppl 6):72-7.
222 Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, et al. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 1994;32:105-14.
223 De Wilde JE, Geerts S, Van Dorpe J, Bruhwyler J, Geczy J. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatr Scand 1996;94:404-10.
224 Wiesel FA, Raaflaub J, Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol 1985;28:89-95.
225 Zeeh J, Fuchs L, Bergmann W, Antonin KH, Degel F, Bieck P, et al. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. Eur J Clin Pharmacol 1996;49:387-91.
226 Rosenzweig P, Patat A, Curet O, Durrieu G, Dubruc C, Zieleniuk I, et al. Clinical pharmacology of befloxatone: a brief review. J Affect Disord 1998;51:305-12.
227 Bruhwyler J, Liegeois JF, Geczy J. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol Res 1997;36:23-33.
228 Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995;17:39-46.
229 Norman TR, Burrows GD. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder. J Neural Transm Suppl 1989;28:53-63.
230 Sheehan DV. Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia. Psychiatr Clin North Am 1985;8:49-62.
231 Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990;47:935-41.
232 Kayser A, Robinson DS, Yingling K, Howard DB, Corcella J, Laux D. The influence of panic attacks on response to phenelzine and amitriptyline in depressed outpatients. J Clin Psychopharmacol 1988;8:246-53.
233 Gorman J, Liebowitz MR, Fyer AJ, Levitt M, Baron M, Davies S, et al. Platelet monoamine oxidase activity in patients with panic disorder. Biol Psychiatry 1985;20:852-7.
234 Balon R, Rainey JM, Pohl R, Yeragani VK, Oxenkrug GF, McCauley RB. Platelet monoamine oxidase activity in panic disorder. Psychiatry Res 1987;22:37-41.
235 Norman TR, Acevedo A, McIntyre IM, Judd FK, Burrows GD. A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks. J Affect Disord 1988;15:127-30.
236 Deckert J, Catalano M, Syagailo YV, Bosi M, Okladnova O, Di Bella D, et al. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 1999;8:621-4.
237 Hamilton SP, Slager SL, Heiman GA, Haghighi F, Klein DF, Hodge SE, et al. No genetic linkage or association between a functional promoter polymorphism in the monoamine oxidase-A gene and panic disorder. Mol Psychiatry 2000;5:465-6.
238 Owens MJ. Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety 1996-97;4:153-9.
239 Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-9.
240 Wesner RB, Noyes R Jr. Tolerance to the therapeutic effect of phenelzine in patients with panic disorder. J Clin Psychiatry 1988;49:450-1.
241 Ries RK, Wittkowsky AK. Synergistic action of alprazolam with tranylcypromine in drug-resistant atypical depression with panic attacks. Biol Psychiatry 1986;21:522-6.
242 Deicken RF. Combined alprazolam and phenelzine treatment of refractory depression with panic attacks. Biol Psychiatry 1987;22:762-6.
243 Garcia-Borreguero D, Lauer CJ, Ozdaglar A, Wiedemann K, Holsboer F, Krieg JC. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. Pharmacopsychiatry 1992;25:261-4.
244 Bakish D, Saxena BM, Bowen R, D'Souza J. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16(Suppl 2):S77-S82.
245 van Vliet IM, Westenberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 1993;112:483-9.
246 van Vliet IM, den Boer JA, Westenberg HG, Slaap BR. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 1996;16:299-306.
247 Tiller JW, Bouwer C, Behnke K. Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. Int Clin Psychopharmacol 1997;12(Suppl 6):S27-S30.
248 Tiller JW, Bouwer C, Behnke K, International Panic Disorder Study Group. Moclobemide and fluoxetine for panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 1):S7-S10.
249 Kruger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 1):S19-S24.
250 Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999;174:205-12.
251 Regnier B. Good clinical practice. Eur J Clin Microbiol Infect Dis 1990;9:519-22.
252 White WF, Dichter MA, Snodgrass SR. Benzodiazepine binding and interactions with the GABA receptor complex in living cultures of rat cerebral cortex. Brain Res 1981;215:162-76.
253 Schoch P, Richards JG, Haring P, Takacs B, Stahli C, Staehelin T, et al. Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature 1985;314:168-71.
254 Whiting PJ, Bonnert TP, McKernan RM, Farrar S, Le Bourdelles B, Heavens RP, et al. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann NY Acad Sci 1999;868:645-53.
255 Im HK, Im WB, Hamilton BJ, Carter DB, Vonvoigtlander PF. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors. Mol Pharmacol 1993;44:866-70.
256 Wafford KA, Bain CJ, Whiting PJ, Kemp JA. Functional comparison of the role of gamma subunits in recombinant human gamma-aminobutyric acidA/benzodiazepine receptors. Mol Pharmacol 1993;44:437-42.
257 Ducic I, Puia G, Vicini S, Costa E. Triazolam is more efficacious than diazepam in a broad spectrum of recombinant GABAA receptors. Eur J Pharmacol 1993;244:29-35.
258 Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric acid-gated Cl-currents. Mol Pharmacol 1991;39:691-6.
259 White WF, Dichter MA, Snodgrass SR. Benzodiazepine binding and interactions with the GABA receptor complex in living cultures of rat cerebral cortex. Brain Res 1981;215:162-76.
260 Study RE, Barker JL. Diazepam and (-)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA 1981;78:7180-4.
261 Mathers DA. Spontaneous and GABA-induced single channel currents in cultured murine spinal cord neurons. Can J Physiol Pharmacol 1985;63:1228-33.
262 Paul SM, Marangos PJ, Skolnick P. The benzodiazepine-GABA-chloride ionophore receptor complex: common site of minor tranquilizer action. Biol Psychiatry 1981;16:213-29.
263 Constanti A, Krnjevic K, Nistri A. Intracellular injections of GABA have a hyperpolarizing effect on motoneurones. J Physiol 1979;293:60P-61P.
264 Jahnsen H, Laursen AM. The effects of a benzodiazepine on the hyperpolarizing and the depolarizing responses of hippocampal cells to GABA. Brain Res 1981;207:214-7.
265 Mayer ML, Higashi H, Shinnick-Gallagher P, Gallagher JP. A hyperpolarizing GABA response associated with a conductance decrease. Brain Res 1981;222:204-8.
266 Arenson MS, Nistri A. The inhibitory amino acid GABA hyperpolarizes motor axons: an intracellular study. Experientia 1983;39:225-8.
267 Bergström DA, Walters JR. Dopamine attenuates the effects of GABA on single unit activity in the globus pallidus. Brain Res 1984;310:23-33.
268 Toth K, Freund TF, Miles R. Disinhibition of rat hippocampal pyramidal cells by GABAergic afferents from the septum. J Physiol 1997;500:463-74.
269 Rivera C, Voipio J, Payne JA, Ruusuvuori E, Lahtinen H, Lamsa K, et al. The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 1999;397:251-5.
270 Jackson MF, Esplin B, Capek R. Activity-dependent enhancement of hyperpolarizing and depolarizing gamma-aminobutyric acid (GABA) synaptic responses following inhibition of GABA uptake by tiagabine. Epilepsy Res 1999;37:25-36.
271 Szalisznyo K, Erdi P. Depolarizing/hyperpolarizing effects of the GABAA synapse have a beneficial role in synaptic weight resetting in the hippocampus. Neuroreport 2000;11:3559-63.
272 Perkins KL, Wong RK. The depolarizing GABA response. Can J Physiol Pharmacol 1997;75:516-9.
273 Duchen MR. Excitation of mouse motoneurones by GABA-mediated primary afferent depolarization. Brain Res 1986;379:182-7.
274 Mercuri NB, Calabresi P, Stefani A, Stratta F, Bernardi G. GABA depolarizes neurons in the rat striatum: an in vivo study. Synapse 1991;8:38-40.
275 Mienville JM. Persistent depolarizing action of GABA in rat Cajal-Retzius cells. J Physiol 1998;512:809-17.
276 Hales TG, Sanderson MJ, Charles AC. GABA has excitatory actions on GnRH-secreting immortalized hypothalamic (GT1-7) neurons. Neuroendocrinology 1994;59:297-308.
277 Nistri A, Berti C. GABA-induced depolarizing responses of the frog spinal cord can be either enhanced or antagonized by the benzodiazepine midazolam and the methylxanthine caffeine. Neurosci Lett 1984;47:277-81.
278 Backus KH, Kettenmann H, Schachner M. Effect of benzodiazepines and pentobarbital on the GABA-induced depolarization in cultured astrocytes. Glia 1988;1:132-40.
279 Decavel C, Van den Pol AN. GABA: a dominant neurotransmitter in the hypothalamus. J Comp Neurol 1990;302:1019-37.
280 Chagnac-Amitai Y, Connors BW. Horizontal spread of synchronized activity in neocortex and its control by GABA-mediated inhibition. J Neurophysiol 1989;61:747-58.
281 Massotti M. Electroencephalographic investigations in rabbits of drugs acting at GABA-benzodiazepine-barbiturate/picrotoxin receptors complex. Pharmacol Biochem Behav 1985;23:661-70.
282 Pellegrini A, Curro-Dossi R, Ermani M, Zanotto L, Testa G. On the intracortical activity during recruiting responses: an analysis of laminar profiles before and after topical application of GABA to the cortex. Exp Brain Res 1987;66:409-20.
283 Reiman EM, Fusselman MJ, Fox PT, Raichle ME. Neuroanatomical correlates of anticipatory anxiety. Science 1989;243:1071-4 (errata corrige Science 1992;256:1696).
284 Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature 1984;310:683-5.
285 Fabre LF Jr. Pilot open label study with alprazolam (U31, 889) in outpatients with neurotic depression. Curr Ther Res Clin Exp 1976;19:661-8.
286 Fabre LF Jr, Gainey A, Kemple S. Pilot open-label study of alprazolam (U-31,889) in anxious alcoholicout-patients. J Int Med Res 1977;5:26-32.
287 Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) 1982;77:229-33.
288 Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Davies SR, et al. Alprazolam in the treatment of panic disorders. J Clin Psychopharmacol 1986;6:13-20.
289 Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-22.
290 Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103.
291 Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993;150:1210-5.
292 Pecknold J, Luthe L, Munjack D, Alexander P. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314-21.
293 Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand 1991;Suppl 365:18-27.
294 Kahn JP, Stevenson E, Topol P, Klein DF. Agitated depression, alprazolam, and panic anxiety. Am J Psychiatry 1986;143:1172-3.
295 Deltito JA, Argyle N, Klerman GL. Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. J Clin Psychiatry 1991;52:121-7 (comment in: J Clin Psychiatry 1991;52:434).
296 Sheikh JI, Swales PJ. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. Int J Psychiatry Med 1999;29:107-17 (comment in: Int J Psychiatry Med 1999;29:91-5).
297 Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998;18(Suppl 2):12S-18S.
298 Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51-60.
299 Lepola UM, Rimon RH, Riekkinen PJ. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993;8:115-8.
300 Lahti RA, Sethy VH, Barsuhn C, Hester JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983;22:1277-82.
301 Pyke RE, Greenberg HS. Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989;9:15-21.
302 Fleishaker JC, Greist JH, Jefferson JW, Sheridan AQ. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:28-35.
303 Davidson JRT, Beitman B, Greist JH, Maddock RJ, Lewis CP, Sheridan AQ, et al. Adinazolam sustained-release treatment of panic disorder: a double-blind study. J Clin Psychopharmacol 1994;14:255-63.
304 Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, et al. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. J Clin Psychiatry 1995;56:202-10.
305 Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 1998;50:265-74.
306 Magarinos AM, Deslandes A, McEwen BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999;371:113-22.
307 Lorizio A. Sul trattamento dello stato di male epilettico con il clonazepam (RO 5-4023 - Rivotril). Riv Neurobiol 1972;18:233-40.
308 Rett A. Möglichkeiten und Grenzen der Clonazepam-Therapie im Kindesalter. Wien Klin Wochenschr 1971;83:725-34.
309 Beaudry P, Fontaine R, Chouinard G, Annable L. An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:589-92.
310 Pols H, Zandbergen J, Lousberg H, de Loof C, Griez E. Low doses of clonazepam in the treatment of panic disorder. Can J Psychiatry 1991;36:302-3.
311 Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis 1986;174:477-82.
312 Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992;17:78-80.
313 Kutcher SP, MacKenzie S. Successful clonazepam treatment of adolescents with panic disorder. J Clin Psychopharmacol 1988;8:299-301.
314 Biederman J. Clonazepam in the treatment of prepubertal children with panic-like symptoms. J Clin Psychiatry 1987;48(Suppl 10):38-42.
315 Pollack MH, Tesar GE, Rosenbaum JF, Spier SA. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986;6:302-4.
316 Spier SA, Tesar GE, Rosenbaum JF, Woods SW. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986;47:238-42.
317 Tesar GE. High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience. J Clin Psychiatry 1990;51(Suppl 5):4-10; discussion 50-53.
318 Herman JB, Rosenbaum JF, Brotman AW. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 1987;7:175-8.
319 Tesar GE, Rosenbaum JF, Pollack MH, Herman JB, Sachs GS, Mahoney EM, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry 1987;48(Suppl 10):16-21.
320 Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.
321 Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-8.
322 Svebak S, Cameron A, Levander S. Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. J Clin Psychiatry 1990;51(Suppl 5):14-7; discussion 50-3.
323 Lima L, Carreira I, Morales M, Silva C, Casique M. Tratamiento de pacientes con trastorno de panico y elevada excreción urinaria de MHPG con imipramina o clonazepam. Invest Clin 1992;33(1):39-52.
324 Valença AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr 2000;58:1025-9.
325 Jacobs RJ, Davidson JR, Gupta S, Meyerhoff AS. The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manag Care 1997;3:1187-96.
326 Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-63.
327 Rosenbaum JF, Moroz G, Bowden CL, Clonazepam Panic Disorder Dose-Response Study Group. Clonazepam in the treatment of panic disorder with or without agoraphobia: adose-response study of efficacy, safety, and discontinuance. J Clin Psychopharmacol 1997;17:390-400.
328 Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999;60:604-12.
329 Worthington JJ 3rd, Pollack MH, Otto MW, McLean RY, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull 1998;34:199-205.
330 Sethy VH, Hodges DH Jr. Role of beta-adrenergic receptors in the antidepressant activity of alprazolam. Res Commun Chem Pathol Pharmacol 1982;36:329-32.
331 Hosoda K, Duman RS. Regulation of beta 1-adrenergic receptor mRNA and ligand binding by antidepressant treatments and norepinephrine depletion in rat frontal cortex. J Neurochem 1993;60:1335-43.
332 Paetsch PR, Greenshaw AJ. Effects of chronic antidepressant treatment on beta-adrenoceptor subtype binding in the rat cerebral cortex and cerebellum. Mol Chem Neuropathol 1993;20:21-31.
333 Owens MJ, Bissette G, Nemeroff CB. Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse 1989;4:196-202.
334 Owens MJ, Vargas MA, Knight DL, Nemeroff CB. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther 1991;258:349-56.
335 Owens MJ, Vargas MA, Nemeroff CB. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: implications for a role for CRF in the pathogenesis of anxiety disorders. J Psychiatr Res 1993;27(Suppl 1):209-20.
336 Skelton KH, Nemeroff CB, Knight DL, Owens MJ. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 2000;20:1240-8.
337 Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in ratbrain. Therapeutic implications. J Clin Invest 1991;87:831-7.
338 Kalogeras KT, Calogero AE, Kuribayiashi T, Khan I, Gallucci WT, Kling MA, et al. In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. J Clin Endocrinol Metab 1990;70:1462-71.
339 Kalin NH, Shelton SE, Turner JG. Effects of alprazolam on fear-related behavioral, hormonal, and catecholamine responses in infant rhesus monkeys. Life Sci 1991;49:2031-44.
340 Rohrer T, von Richthofen V, Schulz C, Beyer J, Lehnert H. The stress-, but not corticotropin-releasing hormone-induced activation of the pituitary-adrenal axis in man is blocked by alprazolam. Horm Metab Res 1994;26:200-6.
341 Curtis GC, Abelson JL, Gold PW. Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 1997;41:76-85.
342 Abelson JL, Curtis GC, Cameron OG. Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res 1996;30:79-93.
343 Lahti RA, Sethy VH, Barsuhn C, Hester JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983;22:1277-82.
344 Srisurapanont M, Boonyanaruthee V. Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect. J Med Assoc Thai 1997;80:183-8.
345 Skelton KH, Owens MJ, Nemeroff CB. The neurobiology of urocortin. Regul Pept 2000;93:85-92.
346 Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, et al. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA 1996;93:1619-23.
347 Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida OF. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 1997;99:962-6.
348 Faravelli C, Webb T, Ambonetti A, Fonnesu F, Sessarego A. Prevalence of traumatic early life events in 31 agoraphobic patients with panic attacks. Am J Psychiatry 1985;142:1493-4.
349 Servant D, Parquet PJ. Early life events and panic disorder: course of illness and comorbidity. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:373-9.
350 Shekhar A. Effects of treatment with imipramine and clonazepam on an animal model of panic disorder. Biol Psychiatry 1994;36:748-58.
351 Sakanaka M, Shibasaki T, Lederis K. Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex. Brain Res 1986;382:213-38.
352 Ottersen OP. Connections of the amygdala of the rat. IV: Corticoamygdaloid and intraamygdaloid connections as studied with axonal transport of horseradish peroxidase. J Comp Neurol 1982;205:30-48.
353 Gray TS, Carney ME, Magnuson DJ. Direct projections from the central amygdaloid nucleus to the hypothalamic paraventricular nucleus: possible role in stress-induced adrenocorticotropin release. Neuroendocrinology 1989;50:433-46.
354 Gray TS. Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress. Ann NY Acad Sci 1993;697:53-60.
355 Dai J, Van Der Vliet J, Swaab DF, Buijs RM. Postmortem anterograde tracing of intrahypothalamic projections of the human dorsomedial nucleus of the hypothalamus. J Comp Neurol 1998;401:16-33.
356 Ter Horst GJ, Luiten PG. Phaseolus vulgaris leuco-agglutinin tracing of intrahypothalamic connections of the lateral, ventromedial, dorsomedial and paraventricular hypothalamic nuclei in the rat. Brain Res Bull 1987;18:191-203.
357 Cedarbaum JM, Aghajanian GK. Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique. J Comp Neurol 1978;178:1-16.
358 Kirby LG, Rice KC, Valentino RJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 2000;22:148-62 (errata corrige Neuropsychopharmacology 2000;22:449).
359 Weninger SC, Peters LL, Majzoub JA. Urocortin expression in the Edinger-Westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency. Endocrinology 2000;141:256-63.
360 Yamamoto H, Maeda T, Fujimura M, Fujimiya M. Urocortin-like immunoreactivity in the substantia nigra, ventral tegmental area and Edinger-Westphal nucleus of rat. Neurosci Lett 1998;243:21-4.
361 Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995;378:287-92.
362 Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J Comp Neurol 1999;415:285-312.
363 Slawecki CJ, Somes C, Rivier JE, Ehlers CL. Neurophysiological effects of intracerebroventricular administration of urocortin. Peptides 1999;20:211-8.
364 Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996;273:1561-4.
365 Morin SM, Ling N, Liu XJ, Kahl SD, Gehlert DR. Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience 1999;92:281-91.
366 Kozicz T, Yanaihara H, Arimura A. Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J Comp Neurol 1998;391:1-10.
367 Cepoi D, Sutton S, Arias C, Sawchenko P, Vale WW. Ovine genomic urocortin: cloning, pharmacologic characterization, and distribution of central mRNA. Mol Brain Res 1999;68:109-18.
368 Takahashi K, Totsune K, Sone M, Murakami O, Satoh F, Arihara Z, et al. Regional distribution of urocortin-like immunoreactivity and expression of urocortin mRNA in the human brain. Peptides 1998;19:643-7.
369 Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836-40 (erratum 5759).
370 Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-4.
371 Lovenberg TW, Chalmers DT, Liu C, De Souza EB. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995;136:4139-42.
372 McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des 1999;5:289-315.
373 Miyata I, Shiota C, Ikeda Y, Oshida Y, Chaki S, Okuyama S, et al. Cloning and characterization of a short variant of the corticotropin-releasing factor receptor subtype from rat amygdala. Biochem Biophys Res Commun 1999;256:692-6.
374 Miyata I, Shiota C, Chaki S, Okuyama S, Inagami T. Localization and characterization of a short isoform of the corticotropin-releasing factor receptor type 2alpha (CRF2-tr) in the rat brain. Biochem Biophys Res Commun 2001;280:553-7.
375 Sajdyk TJ, Gehlert DR. Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala. Brain Res 2000; 877: 226-234.
376 Sajdyk TJ, Schober DA, Gehlert DR, Shekhar A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav Brain Res 1999;100:207-15.
377 Parrott RF, Vellucci SV, Goode JA. Behavioral and hormonal effects of centrally injected "anxiogenic" neuropeptides in growing pigs. Pharmacol Biochem Behav 2000;65:123-9.
378 Wang L, Martinez V, Vale W, Taché Y. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats. Brain Res 2000;855:47-57.
379 Koob GF, Heinrichs SC. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999;848:141-52.
380 Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996;273:1561-4.
381 Wagner HR, Reches A, Fahn S. Clonazepam-induced up-regulation of serotonin1 binding sites in frontal cortex of rat. Neuropharmacology 1985;24:953-6.
382 Chung Hwang E, Van Woert MH. Antimyoclonic action of clonazepam: the role of serotonin. Eur J Pharmacol 1979;60:31-40.
383 Wagner HR, Reches A, Yablonskaya E, Fahn S. Clonazepam-induced up-regulation of serotonin1 and serotonin2 binding sites in rat frontal cortex. Adv Neurol 1986;43:645-51.
384 Lima L, Salazar M, Trejo E. Modulation of 5HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:663-77.
385 Mizuta T, Segawa T. Chronic effects of imipramine and lithium on postsynaptic 5-HT1A and 5-HT1B sites and on presynaptic 5-HT3 sites in rat brain. Jpn J Pharmacol 1988;47:107-13.
386 Le Poul E, Lima L, Laporte AM, Even C, Doucet E, Fattaccini CM, et al. Récepteurs centraux de la sérotonine et traitements chroniques avec un inhibiteur sélectif de la recapture de la sérotonine chez le rat: effets comparés de la fluoxétine et de la paroxétine. Encéphale 1995;21:123-32.
387 Czachura JF, Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn-Schmiedebergs Arch Pharmacol 2000;362:266-75.
388 Hjorth S, Auerbach SB. Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology 1994;33:331-4.
389 Nardi AE, Valença AM, Nascimento I, Mezzasalma MA, Zin WA. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res 2000;94:179-84.
390 Taylor CB, Kenigsberg ML, Robinson JM. A controlled comparison of relaxation and diazepam in panic disorder. J Clin Psychiatry 1982;43:423-5.
391 Ghoneim MM, Hinrichs JV, Noyes R Jr, Anderson DJ. Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia. Neuropsychobiology 1984;11:229-35.
392 Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;47:458-60.
393 Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-23.
394 Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90-3.
395 Jolas T, Nestler EJ, Aghajanian GK. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 2000;95:433-43.
396 Rainnie DG. Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J Neurophysiol 1999;82:69-85.
397 Lovick TA. Involvement of GABA in medullary raphe-evoked modulation of neuronal activity in the periaqueductal grey matter in the rat. Exp Brain Res 2001;137:214-8.
398 Shefner SA, Osmanovic SS. GABAA and GABAB receptors and the ionic mechanisms mediating their effects on locus coeruleus neurons. Prog Brain Res 1991;88:187-95.
399 Ennis M, Aston-Jones G. GABA-mediated inhibition of locus coeruleus from the dorsomedial rostral medulla. J Neurosci 1989;9:2973-81.
400 Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991;88:47-75.
401 Leonard BE. The role of noradrenaline in depression: a review. J Psychopharmacol 1997;11(Suppl 4):S39-S47.
402 Kawaguchi Y, Shindou T. Noradrenergic excitation and inhibition of GABAergic cell types in rat frontal cortex. J Neurosci 1998;18:6963-76.
403 Abellan MT, Adell A, Honrubia MA, Mengod G, Artigas F. GABAB-RI receptors in serotonergic neurons: effects of baclofen on 5-HT output in rat brain. Neuroreport 2000;11:941-5.
404 Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988;145:1104-9.
405 Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-50.
406 Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-6.
407 Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
408 Bolhuis JJ, Fitzgerald RE, Dijk DJ, Koolhaas JM. The corticomedial amygdala and learning in an agonistic situation in the rat. Physiol Behav 1984;32:575-9.
409 Luiten PG, Koolhaas JM, de Boer S, Koopmans SJ. The cortico-medial amygdala in the central nervous system organization of agonistic behavior. Brain Res 1985;332:283-97.
410 Seggie J. Differential responsivity of corticosterone and prolactin to stress following lesions of the septum or amygdala: implications for psychoneuroendocrinology. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:315-24.
411 Cassell MD, Wright DJ. Topography of projections from the medial prefrontal cortex to the amygdala in the rat. Brain Res Bull 1986;17:321-33.
412 Gallagher M, Schoenbaum G. Functions of the amygdala and related forebrain areas in attention and cognition. Ann NY Acad Sci 1999;877:397-411.
413 Baxter MG, Parker A, Lindner CC, Izquierdo AD, Murray EA. Control of response selection by reinforcer value requires interaction of amygdala and orbital prefrontal cortex. J Neurosci 2000;20:4311-9.
414 Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 1999;19:5473-81.
415 Jackson ME, Moghaddam B. Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. J Neurosci 2001;21:676-81.
416 Garcia R, Vouimba RM, Baudry M, Thompson RF. The amygdala modulates prefrontal cortex activity relative to conditioned fear. Nature 1999;402:294-6.
417 Lesse S. Psychotherapy in combination with antidepressant drugs in severely depressed out-patients-20-year evaluation. Am J Psychother 1978;32:48-73.
418 Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
419 Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord 1986;10 67-75.
420 Reynolds CF 3rd, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999;281:39-45.
421 Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA, Hurley K, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-15.
422 van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998;186:492-9.
423 Pasnau RO. Combining pharmacotherapy with psychotherapy in the treatment of anxiety disorder. Psychiatry Clin Neurosci 1998;52(Suppl Dec):S199-S202.
424 Bakker A, van Dyck R, Spinhoven P, van Balkom AJ. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999;60:831-8.
425 Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994;164:759-69 (comment in: Br J Psychiatry 1994;165:556-9, 1995;166:541-3).
426 Kilic C, Noshirvani H, Basoglu M, Marks I. Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. Psychother Psychosom 1997;66:175-8.
427 de Beurs E, van Balkom AJ, Van Dyck R, Lange A. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatr Scand 1999;99:59-67.
428 Nagy LM, Krystal JH, Charney DS, Merikangas KR, Woods SW. Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. J Clin Psychopharmacol 1993;13:16-24.
429 Cox BJ, Endler NS, Lee PS, Swinson RP. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry 1992;23:175-82.
430 Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993;61:317-26.
431 van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997;185:510-6.
432 Bakker A, van Balkom AJ, Spinhoven P, Blaauw BM, van Dyck R. Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. J Nerv Ment Dis 1998;186:414-9.
433 Klein DF. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 2000;157:1204-11.
434 Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
435 Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992;149:1053-7.
436 Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529-36 (comment in: JAMA 2000;283:2573-4).
437 Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 1996;53:689-94.
438 de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-91.
439 Azhar MZ. Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors. Med J Malaysia 2000;55:402-8.
440 Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995;167:635-41.
441 Bouvard M, Mollard E, Guerin J, Cottraux J. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother Psychosom 1997;66:27-32.
442 Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993;162:776-87 (comment in Br J Psychiatry 1993;162:788-9; discussion 790-4).
443 Gorman JM, Liebowitz MR, Fyer AJ, Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 1989;146:148-61 (comment in: Am J Psychiatry 1990;147:126-7).
444 Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
445 Schoenbaum G, Chiba AA, Gallagher M. Changes in functional connectivity in orbitofrontal cortex and basolateral amygdala during learning and reversal training. J Neurosci 2000;20:5179-89.
446 Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy forobsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:681-9.
447 Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, et al. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 19989;84:1-6.
448 Simpson S, Baldwin B. Neuropsychiatry and SPECT of an acute obsessive-compulsive syndrome patient. Br J Psychiatry 1995;166:390-2.